Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref.
studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Nojomi, 2020
  IRCT20180725040596N2		 RCTlopinavir/ritonavirumifenovir (arbidol)COVID 19 hospitalizedsome concern
50/50 inconclusive
    RECOVERY, 2020
          NCT04381936    		 RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
    		1616/3424 inconclusive
    • inconclusive 3 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
    the trial Steering Committee concluded that there is no beneficial effect of lopinavir-ritonavir in patients hospitalised with COVID-19 and closed randomisation to that treatment arm
    Sekhavati, 2020 RCTlopinavir/ritonavirlopinavir/ritonavirCOVID 19 hospitalizedsome concern
    		56/55 inconclusive
    • inconclusive 51 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
    Sekhavati, 2020 RCTlopinavir/ritonavirhydroxychloroquineCOVID 19 hospitalizedsome concern
    		56/55 inconclusive
    • inconclusive 51 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
    SOLIDARITY (lopi/rito), 2020
          NCT04315948    		 RCTlopinavir/ritonavirstandard of careCOVID 19 hospitalizedsome concern
    		1399/1372 inconclusive
    • inconclusive 0 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 mild to moderate meta-analysis

    ELACOI (lopinavir/ritonavir), 2020
          NCT04252885    		 RCTlopinavir/ritonavirstandard of careCOVID-19 mild to moderatesome concern
    		21/7 inconclusive

      COVID-19 severe or critically meta-analysis

      Cao B, 2020
              ChiCTR2000029308      		 RCTlopinavir/ritonavirstandard of careCOVID-19 severe or criticallysome concern
      		99/100 suggested
      • inconclusive 31 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      • suggested 94 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

       

      - About us - Contact us - Method Made with in Lyon - Credits - Privacy policy - Licence Creative Commons